189 related articles for article (PubMed ID: 24601815)
1. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
2. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
4. Advancing through maintenance in mantle cell lymphoma.
Martin P; Leonard JP
Leuk Lymphoma; 2011 Sep; 52(9):1617-8. PubMed ID: 21699376
[No Abstract] [Full Text] [Related]
5. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
7. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
8. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
[No Abstract] [Full Text] [Related]
9. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
11. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
12. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
13. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.
Dietrich S; Weidle J; Rieger M; Meissner J; Radujkovic A; Ho AD; Dreger P; Witzens-Harig M
Leukemia; 2014 Mar; 28(3):708-9. PubMed ID: 24217198
[No Abstract] [Full Text] [Related]
14. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.
Liu J; Stewart D; Fontaine A; Peters A; Fleury I; Mollica L; Prica A; Buckstein R; Sehn L; Jiang A; Kuruvilla J; Villa D
Leuk Lymphoma; 2020 Oct; 61(10):2492-2496. PubMed ID: 32519592
[No Abstract] [Full Text] [Related]
16. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
Croxtall JD
BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
[No Abstract] [Full Text] [Related]
17. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
18. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Pfreundschuh M
Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
[No Abstract] [Full Text] [Related]
19. NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
Doss S; Garrett Z; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):128-30. PubMed ID: 22403811
[No Abstract] [Full Text] [Related]
20. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]